579 related articles for article (PubMed ID: 34741755)
1. On the Biomedical Properties of Endocannabinoid Degradation and Reuptake Inhibitors: Pre-clinical and Clinical Evidence.
Paredes-Ruiz KJ; Chavira-Ramos K; Orozco-Morales M; Karasu C; Tinkov AA; Aschner M; Santamaría A; Colín-González AL
Neurotox Res; 2021 Dec; 39(6):2072-2097. PubMed ID: 34741755
[TBL] [Abstract][Full Text] [Related]
2. The Endocannabinoid System Modulating Levels of Consciousness, Emotions and Likely Dream Contents.
Murillo-Rodriguez E; Pastrana-Trejo JC; Salas-Crisóstomo M; de-la-Cruz M
CNS Neurol Disord Drug Targets; 2017; 16(4):370-379. PubMed ID: 28240187
[TBL] [Abstract][Full Text] [Related]
3. Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment.
Guindon J; Lai Y; Takacs SM; Bradshaw HB; Hohmann AG
Pharmacol Res; 2013 Jan; 67(1):94-109. PubMed ID: 23127915
[TBL] [Abstract][Full Text] [Related]
4. The fundamental role of the endocannabinoid system in endometrium and placenta: implications in pathophysiological aspects of uterine and pregnancy disorders.
Maia J; Fonseca BM; Teixeira N; Correia-da-Silva G
Hum Reprod Update; 2020 Jun; 26(4):586-602. PubMed ID: 32347309
[TBL] [Abstract][Full Text] [Related]
5. Enhanced endocannabinoid tone as a potential target of pharmacotherapy.
Toczek M; Malinowska B
Life Sci; 2018 Jul; 204():20-45. PubMed ID: 29729263
[TBL] [Abstract][Full Text] [Related]
6. Endocannabinoid Hydrolase Inhibitors: Potential Novel Anxiolytic Drugs.
Zhao H; Liu Y; Cai N; Liao X; Tang L; Wang Y
Drug Des Devel Ther; 2024; 18():2143-2167. PubMed ID: 38882045
[TBL] [Abstract][Full Text] [Related]
7. Targeting Endocannabinoid Signaling: FAAH and MAG Lipase Inhibitors.
van Egmond N; Straub VM; van der Stelt M
Annu Rev Pharmacol Toxicol; 2021 Jan; 61():441-463. PubMed ID: 32867595
[TBL] [Abstract][Full Text] [Related]
8. Untapped endocannabinoid pharmacological targets: Pipe dream or pipeline?
Wilkerson JL; Bilbrey JA; Felix JS; Makriyannis A; McMahon LR
Pharmacol Biochem Behav; 2021 Jul; 206():173192. PubMed ID: 33932409
[TBL] [Abstract][Full Text] [Related]
9. Elevating endocannabinoid levels: pharmacological strategies and potential therapeutic applications.
Pertwee RG
Proc Nutr Soc; 2014 Feb; 73(1):96-105. PubMed ID: 24135210
[TBL] [Abstract][Full Text] [Related]
10. Beyond the Direct Activation of Cannabinoid Receptors: New Strategies to Modulate the Endocannabinoid System in CNS-Related Diseases.
Chicca A; Arena C; Manera C
Recent Pat CNS Drug Discov; 2016; 10(2):122-141. PubMed ID: 27630088
[TBL] [Abstract][Full Text] [Related]
11. Endocannabinoid system: An overview of its potential in current medical practice.
Mouslech Z; Valla V
Neuro Endocrinol Lett; 2009; 30(2):153-79. PubMed ID: 19675519
[TBL] [Abstract][Full Text] [Related]
12. O-hydroxyacetamide carbamates as a highly potent and selective class of endocannabinoid hydrolase inhibitors.
Niphakis MJ; Johnson DS; Ballard TE; Stiff C; Cravatt BF
ACS Chem Neurosci; 2012 May; 3(5):418-26. PubMed ID: 22860211
[TBL] [Abstract][Full Text] [Related]
13. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
Gaetani S; Dipasquale P; Romano A; Righetti L; Cassano T; Piomelli D; Cuomo V
Int Rev Neurobiol; 2009; 85():57-72. PubMed ID: 19607961
[TBL] [Abstract][Full Text] [Related]
14. Endocannabinoid metabolism and transport as targets to regulate intraocular pressure.
Miller S; Daily L; Dharla V; Gertsch J; Malamas MS; Ojima I; Kaczocha M; Ogasawara D; Straiker A
Exp Eye Res; 2020 Dec; 201():108266. PubMed ID: 32979397
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of endocannabinoid neuronal uptake and hydrolysis as strategies for developing anxiolytic drugs.
Batista LA; Gobira PH; Viana TG; Aguiar DC; Moreira FA
Behav Pharmacol; 2014 Sep; 25(5-6):425-33. PubMed ID: 25083569
[TBL] [Abstract][Full Text] [Related]
16. The endocannabinoid system: physiology and pharmacology.
Rodríguez de Fonseca F; Del Arco I; Bermudez-Silva FJ; Bilbao A; Cippitelli A; Navarro M
Alcohol Alcohol; 2005; 40(1):2-14. PubMed ID: 15550444
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.
Walentiny DM; Vann RE; Wiley JL
Neuropharmacology; 2015 Jun; 93():237-42. PubMed ID: 25698527
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the endocannabinoid-regulating enzyme monoacylglycerol lipase elicits a CB
Owens RA; Mustafa MA; Ignatowska-Jankowska BM; Damaj MI; Beardsley PM; Wiley JL; Niphakis MJ; Cravatt BF; Lichtman AH
Neuropharmacology; 2017 Oct; 125():80-86. PubMed ID: 28673548
[TBL] [Abstract][Full Text] [Related]
19. The endocannabinoid system as a potential therapeutic target for pain modulation.
Ulugöl A
Balkan Med J; 2014 Jun; 31(2):115-20. PubMed ID: 25207181
[TBL] [Abstract][Full Text] [Related]
20. Guineensine is a novel inhibitor of endocannabinoid uptake showing cannabimimetic behavioral effects in BALB/c mice.
Nicolussi S; Viveros-Paredes JM; Gachet MS; Rau M; Flores-Soto ME; Blunder M; Gertsch J
Pharmacol Res; 2014 Feb; 80():52-65. PubMed ID: 24412246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
